Votrient pazopanib regulatory update

FDA's Oncologic Drugs Advisory Committee voted 10-0 that GlaxoSmithKline's Votrient pazopanib had a favorable risk-benefit profile for patients with renal cell carcinoma (RCC). ODAC based its decision...